Literature DB >> 9793523

Sclerosis and the Nd:YAG, Q-switched laser with multiple frequency for treatment of telangiectases, reticular veins, and residual pigmentation.

J L Cisneros1, R Del Rio, J Palou.   

Abstract

BACKGROUND: The combination of low concentrations of sclerosing solution and the Nd:YAG, Q-switched laser with multiple (quadruple) frequency provides good results in the treatment of telangiectases and reticular varicose veins of the lower extremities, as well as pigmentation that may appear during sclerotherapy.
OBJECTIVE: This paper is based on a series of patients with telangiectases and reticular veins who were treated with sclerotherapy and the Nd:YAG, Q-switched laser with quadruple frequency.
METHODS: Patients with telangiectases and reticular veins received two or three treatment sessions with polydocanol and the Nd:YAG, Q-switched laser with quadruple frequency. Then, they were assessed a clinical score corresponding to the level of improvement achieved. Residual hematic pigmentation lesions were also eliminated with the laser.
RESULTS: Excellent improvement was evident in 90% of the patients with minimal residual lesions.
CONCLUSIONS: The combined technique of sclerosing solution and the Nd:YAG laser with multiple frequency is a valid alternative for the elimination of telangiectases and reticular veins of the lower limbs. This technique has several advantages, such as the use of low concentrations of sclerosing solution, high patient acceptance levels due to minimal disturbances, and the fact that local anesthesia is unnecessary. Good results are obtained without complications and minimal residual pigmentation. These mild pigmentation can be treated with the Nd:YAG laser.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9793523     DOI: 10.1111/j.1524-4725.1998.tb04084.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  1 in total

1.  A Novel Approach for the Treatment of Spider Veins.

Authors:  Mirsad Mujadzic; Edmond F Ritter; Kenna S Given
Journal:  Aesthet Surg J       Date:  2015-08-04       Impact factor: 4.283

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.